Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Chorismate synthase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0033 | 0.0245 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0098 | 0.1321 | 0.7543 |
Mycobacterium ulcerans | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0098 | 0.1321 | 0.7543 |
Onchocerca volvulus | 0.0124 | 0.1752 | 1 | |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0033 | 0.0245 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.0245 | 1 |
Mycobacterium tuberculosis | Probable chorismate synthase AroF (5-enolpyruvylshikimate-3-phosphate phospholyase) | 0.0106 | 0.1454 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0033 | 0.0245 | 0.0245 |
Loa Loa (eye worm) | hypothetical protein | 0.0124 | 0.1752 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Plasmodium vivax | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Brugia malayi | hypothetical protein | 0.0033 | 0.0245 | 0.1399 |
Toxoplasma gondii | chorismate synthase, putative | 0.0216 | 0.3256 | 0.5 |
Mycobacterium leprae | Chorismate synthase AroF (5-enolpyruvylshikimate-3-phosphate phospholyase). | 0.0106 | 0.1454 | 0.5 |
Brugia malayi | hypothetical protein | 0.0124 | 0.1752 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Chlamydia trachomatis | chorismate synthase | 0.0216 | 0.3256 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0098 | 0.1321 | 0.7543 |
Entamoeba histolytica | hypothetical protein | 0.0033 | 0.0245 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.